After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. On Wednesday, Novartis gave a more ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

Last year, Novartis agreed to buy U.S.-based Mariana Oncology for $1 billion upfront to expand its portfolio of the drugs, ...